A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

NCT02130869 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma
Lymphoma
High-risk Tumor

Interventions

BIOLOGICAL: CD133+ selected autologous stem cell infusion
BIOLOGICAL: IL-2
BIOLOGICAL: hu14.18K322A
DRUG: Busulfan
DRUG: Melphalan
BIOLOGICAL: GM-CSF
DRUG: Bendamustine
DRUG: Etoposide
DRUG: Cytarabine
DRUG: Carboplatin
DEVICE: Haploidentical natural killer cell infusion
BIOLOGICAL: G-CSF
DRUG: Etoposide phosphate
DEVICE: CliniMACS

Sponsor

St. Jude Children's Research Hospital